Inclusion complexes of lamotrigine and hydroxy propyl β-cyclodextrin: Solid state characterization and dissolution studies

Journal of Inclusion Phenomena and Macrocyclic Chemistry

Volumn 65, Issue 3, 2009, Pages 263-268

  Parmar, Komal R ^a   Patel, Kalpesh A ^a   Shah, Sunny R ^a   Sheth, Navin R ^a  

^a SAURASHTRA UNIVERSITY   (India)

Author keywords

Dissolution enhancement; Hydroxy propyl cyclodextrin; Inclusion complexes; Lamotrigine; Solid state characterization

Indexed keywords

EID: 76749113846     PISSN: 09230750     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10847-009-9577-y     Document Type: Article

References (22)

1. Emara, L. H., Badr, R. M., Abd, E. A.: Improving the dissolution and bioavailability of nifedipine using solid dispersions and solubilizers. Drug Dev. Ind. Pharm. 28, 795-807 (2002). doi: 10. 1081/DDC-120005625.
2. Fahr, A., Liu, X.: Drug delivery strategies for poorly water-soluble drugs. Expert Opin. Drug Deliv. 4(4), 403-416 (2007). doi: 10. 1517/17425247. 4. 4. 403.
3. El-Badry, M., Fathy, M. L.: Enhancement of the dissolution and permeation rates of meloxicam by formation of its freeze dried solid dispersions in polyvinylpyrrolidone K-30. Drug Dev. Ind. Pharm. 32, 141-150 (2006). doi: 10. 1080/03639040500465983.
4. Okonogi, S., Puttipipatkhachorn, S.: Dissolution improvement of high drug loaded solid dispersion. AAPS PharmSciTech. 7(2), 52 (2006). doi: 10. 1208/pt070252.
5. De Waard, H., Hinrichs, W. L. J., Visser, M. R., Bologna, C., Frijlink, H. W.: Unexpected differences in dissolution behavior of tablets prepared from solid dispersions with a surfactant physically mixed or incorporated. Int. J. Pharm. 349, 66-73 (2008). doi: 10. 1016/j. ijpharm. 2007. 07. 023.
6. Vogt, M., Kunath, K., Dressman, J. B.: Dissolution enhancement of fenofibrate by micronization, cogrinding and spray-drying: comparison with commercial preparations. Eur. J. Pharm. Biopharm. 68, 283-288 (2008). doi: 10. 1016/j. ejpb. 2007. 05. 010.
7. Shah, J. C., Chen, J. R., Chow, D.: Metastable polymorph of etoposide with higher dissolution rate. Drug Dev. Ind. Pharm. 25(1), 63-67 (1999). doi: 10. 1081/DDC-100102142.
8. Dixit, R. P., Nagarsenker, M. S.: Self-nanoemulsifying granules of ezetimibe: design, optimization and evaluation. Eur. J. Pharm. Sci. 35, 183-192 (2008). doi: 10. 1016/j. ejps. 2008. 06. 013.
9. Nalluri, B. N., Chowdary, K. P. R., Murthy, K. V. R., Hayman, A. R., Becket, G.: Physicochemical characterization and dissolution properties of nimesulide-cyclodextrin binary systems. AAPS PharmSciTech. 4(1), Article 2 (2003).
10. Challa, R., Ahuja, A., Ali, J., Khar, R. K.: Cyclodextrins in drug delivery: an updated review. AAPS PharmSciTech. 6(2), E329-E357 (2005). doi: 10. 1208/pt060243.
11. Takumi, H., Fumitoshi, H., Hidetoshi, A., Yoshihiro, Y., Kaneto, U.: Improvement of solubility and oral bioavailability of 2-(N-Cyanoimino)-5-{(E)-4-styrylbenzylidene}-4-oxothiazolidine (FPFS-410) with antidiabetic and lipid-lowering activities in dogs by 2-hydroxypropyl-b-cyclodextrin. Chem. Pharm. Bull. (Tokyo). 54(3), 344-349 (2006). doi: 10. 1248/cpb. 54. 344.
12. Tirucherai, G. S., Mitra, A. K.: Effect of hydroxypropyl beta cyclodextrin complexation on aqueous solubility, stability, and corneal permeation of acyl ester prodrugs of ganciclovir. AAPS PharmSciTech. 4(3), 45 (2003). doi: 10. 1208/pt040345.
13. O'Donnell, J., Bateman, N.: Lamotrigine overdose in an adult. Clin. Toxicol. 38(6), 659-660 (2000). doi: 10. 1081/CLT-100102017.
14. Chong, E., Dupuis, L.: Therapeutic drug monitoring of lamotrigine. Ann. Pharmacother. 36(5), 917-920 (2002). doi: 10. 1345/aph. 1A252.
15. The Internet Drug Index.: Available at www. rxlist. com/cgi/generic/lamotrigine. htm. Accessed on 10 Dec 2008.
16. Shinde, V. R., Shelake, M. R., Shetty, S. S., Chavan-Patil, A. B., Pore, V. V., Late, S. G.: Enhanced solubility and dissolution rate of lamotrigine by inclusion complexation and solid dispersion technique. J. Pharm. Pharmacol. 60(9), 1121-1129 (2008). doi: 10. 1211/jpp. 60. 9. 0002.
17. Higuchi, T., Connors, K.: Phase solubility techniques. Adv. Anal. Chem. Instrum. 4, 117-212 (1965).
18. US FDA.: http://www. accessdata.fda.gov/scripts/cder/dissolution/dsp_SearchResults_Dissolutions. cfm. Accessed on 15 Dec 2008.
19. Manca, M. L., Zaru, M., Ennas, G., Valenti, D., Cinico, C., Loy, G., Fadda, A. M.: Diclofenac-β-cyclodextrin binary systems: physicochemical characterization and in vitro dissolution and diffusion studies. AAPS PharmSciTech. 6(3), 58 (2005). doi: 10. 1208/pt060358.
20. Mura, P., Maestrelli, F., Cirri, M., Furlanetto, S., Pinzauti, S.: Differential scanning calorimetry as tools in the study of drug-cyclodextrin interactions. J. Therm. Anal. Calorim. 74, 769-777 (2003). doi: 10. 1023/B: JTAN. 0000011009. 46113. 01.
21. Chen, F., Wu, A., Chen, C.: Inclusion complex of carprofen with hydroxypropyl-β-cyclodextrin. J. Incl. Phenom. Macrocycl. Chem. 46, 111-115 (2003). doi: 10. 1023/A: 1025699207208.
22. Loftsson, T., Brewster, M. E.: Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J. Pharm. Sci. 85, 1017-1025 (1996). doi: 10. 1021/js950534b.